Aclaris Therapeutics (ACRS) has released an update to notify the public and investors about its officers.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Aclaris Therapeutics, Inc. has recently undergone significant executive changes, terminating Chief Medical Officer Gail Cawkwell without cause, and offering severance benefits, including a year’s salary and medical coverage. Meanwhile, the Chief Scientific Officer, Joseph Monahan, has agreed to a new employment contract with increased salary and benefits, transitioning to full-time status. Additionally, the company’s CEO and President, Douglas Manion, also parted ways, securing similar severance terms as Dr. Cawkwell. These top-level shifts could indicate strategic realignments within Aclaris as it navigates its future in the pharmaceutical industry.
For further insights into ACRS corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
